MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MBX Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$52.48+2.87 (+5.79%)
Close on Oct 19, 2026
- Market cap
- $2.50B
- P/E (TTM)
- –
- Dividend yield
- –
MBX Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | MBX Biosciences | Industry median |
|---|---|---|
| Market Cap | $2.53B | $166.30M |
| Enterprise Value | $2.11B | $88.19M |
| PB Ratio | 6.17 | 2.03 |
| P/TBV Ratio | 6.17 | 2.29 |
Income (trailing twelve months)
| Measure | MBX Biosciences | Industry median |
|---|---|---|
| Operating Income | -$117.92M | -$21.40M |
| Net Income | -$104.32M | -$22.46M |
| EBITDA | -$117.92M | -$16.91M |
| EPS (Diluted) | -$2.40 | -$0.83 |
Returns
| Measure | MBX Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -33.2% | -53.2% |
| Return on Assets (ROA) | -31.3% | -40.9% |
| Return on Capital Employed (ROCE) | -28.6% | -38.1% |
Balance sheet
| Measure | MBX Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $418.60M | $61.43M |
| Net Cash (Debt) | $418.60M | $15.35M |
| Net Cash Per Share | $8.69 | $0.66 |
| Equity (Book Value) | $409.54M | $49.09M |
| Book Value Per Share | $8.50 | $1.37 |
| Tangible Book Value | $409.54M | $23.52M |
| Working Capital | $404.20M | $76.81M |
Financial position
| Measure | MBX Biosciences | Industry median |
|---|---|---|
| Current Ratio | 18.08 | 3.34 |
| Quick Ratio | 17.69 | 2.44 |
Cash flow (trailing twelve months)
| Measure | MBX Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$82.67M | -$12.35M |
| Capital Expenditures | -$2.53M | -$1.08M |
| Free Cash Flow | -$85.20M | -$20.22M |
| FCF Per Share | -$1.77 | -$0.42 |
Efficiency
| Measure | MBX Biosciences | Industry median |
|---|---|---|
| Profits Per Employee | -$1.66M | -$703.34K |
| Employee Count | 63 | 74 |
Dividends and yields
| Measure | MBX Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -4.13% | -23.3% |
| FCF Yield | -3.37% | -8.72% |
Shares
| Measure | MBX Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 48,160,100 | 58,127,000 |
| Shares Change (QoQ) | 0.80% | 0.54% |
| Float | 20,580,200 | 49,136,700 |
| Shares Held by Insiders | 57.3% | 11.6% |
| Shares Held by Institutions | 115.2% | 59.4% |
Scores
| Measure | MBX Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | 56.81 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from MBX Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.